Enochian Biosciences Inc (OTCMKTS:ENOB) Director Purchases $268,000.00 in Stock

Enochian Biosciences Inc (OTCMKTS:ENOB) Director Rene Sindlev bought 40,000 shares of the firm’s stock in a transaction on Monday, June 3rd. The shares were acquired at an average price of $6.70 per share, for a total transaction of $268,000.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Rene Sindlev also recently made the following trade(s):

  • On Tuesday, May 28th, Rene Sindlev bought 36,200 shares of Enochian Biosciences stock. The shares were acquired at an average price of $6.61 per share, for a total transaction of $239,282.00.
  • On Tuesday, May 21st, Rene Sindlev bought 20,000 shares of Enochian Biosciences stock. The shares were acquired at an average price of $5.75 per share, for a total transaction of $115,000.00.

Shares of Enochian Biosciences stock traded down $0.09 on Friday, reaching $4.50. 493,400 shares of the stock were exchanged, compared to its average volume of 58,391. The firm’s 50 day simple moving average is $5.81. Enochian Biosciences Inc has a one year low of $3.32 and a one year high of $9.50.

Enochian Biosciences (OTCMKTS:ENOB) last issued its quarterly earnings data on Thursday, May 16th. The company reported ($0.13) EPS for the quarter.

A hedge fund recently bought a new stake in Enochian Biosciences stock. Marshall Wace LLP purchased a new stake in Enochian Biosciences Inc (OTCMKTS:ENOB) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 8,648 shares of the company’s stock, valued at approximately $60,000.

About Enochian Biosciences

Enochian Biosciences Inc, a biopharmaceutical company, identifies, develops, manufactures, and commercializes gene therapies for HIV/AIDS and cancer patients. Its lead candidate include ENO-1001 a genetically modified cell therapy for patients with HIV/AIDS. It is also developing ENO-2001, an HIV vaccine; and additional compounds, such as ENO-4001, ENO-4002, ENO-3001, and ENO-5001 that are in discovery stage for prevention of relapse in colon cancer patients.

Read More: What is the return on assets (ROA) ratio?

Receive News & Ratings for Enochian Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enochian Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.